Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
5.64 EUR | +2.17% | -5.53% | +31.78% |
Apr. 17 | OSE: licensing agreement with AbbVie enters into force | CF |
Apr. 17 | OSE Immunotherapeutics Finalizes Drug License, Collaboration Deal With AbbVie | MT |
Sales 2023 | 2.23M 2.38M | Sales 2024 * | 37.83M 40.4M | Capitalization | 122M 130M |
---|---|---|---|---|---|
Net income 2023 | -23M -24.56M | Net income 2024 * | -5M -5.34M | EV / Sales 2023 | 36.2 x |
Net Debt 2023 * | 33.7M 35.99M | Net Debt 2024 * | 46.6M 49.76M | EV / Sales 2024 * | 4.45 x |
P/E ratio 2023 |
-3.63
x | P/E ratio 2024 * |
-13.1
x | Employees | 62 |
Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 72.4% |
Latest transcript on OSE Immunotherapeutics
1 day | +2.17% | ||
1 week | -5.53% | ||
Current month | +16.05% | ||
1 month | +16.05% | ||
3 months | +40.65% | ||
6 months | +31.78% | ||
Current year | +31.78% |
Managers | Title | Age | Since |
---|---|---|---|
Founder | 69 | 04-11-16 | |
Nicolas Poirier
CEO | Chief Executive Officer | 42 | 16-05-30 |
Director of Finance/CFO | - | 16-04-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Founder | 69 | 04-11-16 | |
Director/Board Member | 66 | 23-06-21 | |
Director/Board Member | 66 | 22-02-17 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-30 | 5.64 | +2.17% | 95,863 |
24-04-29 | 5.52 | -0.72% | 128,028 |
24-04-26 | 5.56 | -0.71% | 87,408 |
24-04-25 | 5.6 | -0.71% | 158,909 |
24-04-24 | 5.64 | -5.53% | 240,936 |
Real-time Euronext Paris, April 30, 2024 at 11:35 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+31.78% | 130M | |
+0.17% | 42.19B | |
+10.92% | 42.24B | |
+44.30% | 40.15B | |
-6.20% | 28.31B | |
+5.23% | 24.63B | |
-24.79% | 18.2B | |
+26.69% | 12.01B | |
-3.13% | 11.76B | |
+6.57% | 10.4B |
- Stock Market
- Equities
- OSE Stock